The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system SAN DIEGO, Jan. 20, 2026 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
